Pfizer quarterly profit misses estimates
[BENGALURU] Pfizer Inc, which closed its US$14 billion acquisition of Medivation Inc in September, reported a lower-than-expected profit, hit by lower demand for products set to go off patent.
The largest US drugmaker posted a net income US$775 million, or 13 US cents per share, in the fourth quarter, compared with a loss of US$172 million, or three US cents per share, a year earlier.
Excluding items, the company earned 47 US cents per share, missing the average analysts' estimate of 50 US cents per share, according to Thomson Reuters I/B/E/S.
The company's revenue slipped three per cent to US$13.63 billion, due to a strong US dollar and fewer selling days compared to the year-ago quarter, but was roughly in line with estimates.
Those lost days resulted in a negative impact on quarterly revenue by about US$750 million compared to the prior-year quarter.
The company forecast adjusted profit of US$2.50-US$2.60 per share on revenue of US$52 billion-US$54 billion in 2017. Analysts on average were expecting earnings of US$2.56 per share and revenue of US$54.03 billion.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue